Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.
D000368:Aged; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008935:Mitoguazone / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D008935:Mitoguazone